期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
基于BV2小胶质细胞极化探索片仔癀抗炎机制 被引量:7
1
作者 舒海洋 樊丹采 +3 位作者 赵宁 吕诚 吕爱平 何小鹃 《中国实验方剂学杂志》 CAS CSCD 北大核心 2020年第5期48-53,共6页
目的:从小鼠小胶质瘤细胞(BV2)极化角度探索片仔癀(PTH)的抗炎作用机制。方法:将对数生长期的BV2细胞分为空白组,M1模型组[脂多糖(LPS)100μg·L^-1+干扰素-γ(IFN-γ)10μg·L^-1],M1片仔癀组[LPS 100μg·L^-1+IFN-γ10μ... 目的:从小鼠小胶质瘤细胞(BV2)极化角度探索片仔癀(PTH)的抗炎作用机制。方法:将对数生长期的BV2细胞分为空白组,M1模型组[脂多糖(LPS)100μg·L^-1+干扰素-γ(IFN-γ)10μg·L^-1],M1片仔癀组[LPS 100μg·L^-1+IFN-γ10μg·L^-1+PTH 0.4 g·kg^-1],M2模型组[白细胞介素-4(IL-4)20μg·L^-1],M2片仔癀组[IL-420μg·L^-1+PTH0.4 g·kg^-1],给以相应处理。通过酶联免疫吸附测定(ELISA)检测细胞上清中肿瘤坏死因子-α(TNF-α),一氧化氮(NO),白细胞介素^-10(IL^-10),转化生长因子-β1(TGF-β1)的含量,使用实时荧光定量聚合酶链式反应(Real-time PCR)检测细胞中一氧化氮诱导合酶(i NOS),精氨酸^-1(Arg-1)mRNA的水平,蛋白免疫印迹法(Western blot)检测细胞中i NOS,p-STAT1,p-STAT3,Arg-1,p-STAT6蛋白表达情况。结果:与空白组比较,M1模型组上清TNF-α,NO含量显著升高(P<0.01),细胞i NOS mRNA,i NOS,p-STAT1,p-STAT3蛋白水平显著升高(P<0.01),而与M1模型组比较,M1片仔癀组上清TNF-α及NO的含量显著下调(P<0.01),细胞i NOS mRNA显著下调(P<0.01),i NOS,p-STAT1,p-STAT3蛋白水平也明显下调(P<0.05,P<0.01)。与空白组比较,M2模型组细胞培养上清中IL^-10及TGF-β1含量显著升高(P<0.01),细胞Arg-1 mRNA,Arg-1,p-STAT6蛋白水平显著升高(P<0.01)。与M2模型组比较,M2片仔癀组上清中IL-10及TGF-β1含量明显上调(P<0.05,P<0.01),细胞Arg-1mRNA水平,Arg-1及p-STAT6蛋白水平明显上调(P<0.05,P<0.01)。结论:片仔癀可以通过调节BV2的极化发挥抗炎作用。 展开更多
关键词 片仔癀 小胶质细胞 极化 抗炎 中医药
原文传递
Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration(SPIRIT-TCM Extension 2018) 被引量:10
2
作者 DAI Liang CHENG Chung-wah +6 位作者 TIAN Ran ZHONG Linda LD LI You-ping lyu ai-ping CHAN An-wen SHANG Hong-cai BIAN Zhao-xiang 《Chinese Journal of Integrative Medicine》 SCIE CAS CSCD 2019年第1期71-79,共9页
Traditional Chinese Medicine(TCM) is one of the oldest systems of medicine. More and more attention has been paid to TCM application, but the variable quality of clinical trials with TCM impedes its widespread accepta... Traditional Chinese Medicine(TCM) is one of the oldest systems of medicine. More and more attention has been paid to TCM application, but the variable quality of clinical trials with TCM impedes its widespread acceptance. The Standard Protocol Items: Recommendations for Interventional Trials(SPIRIT) 2013 Statement has established guidelines for designing clinical trials to ensure that the trial results are accurate and reliable. However, there are difficulties when applying SPIRIT 2013 Statement to trials with TCM, due to the unique theory and the characteristic of TCM intervention. An Extension to the original SPIRIT was developed to ensure the quality of trial design with TCM. As Chinese herbal formulae, acupuncture and moxibustion are common and representative interventions in TCM practice, the executive working group determined that the SPIRIT-TCM Extension focus on these three interventions. Extension was developed through initiation, 3 rounds of Delphi consensus survey, and finalizing expert meeting. Seven items from the SPIRIT 2013 Statement were modified, namely, "title", "background and rationale", "objectives", "eligibility criteria", "interventions", "outcomes", and "data collection methods". The Extension includes the introduction of the concept of TCM pattern and 3 major TCM interventions, with examples and explanations. The SPIRIT-TCM Extension 2018 provides suggestion for investigators in designing high quality TCM clinical trials. It is expected that wide dissemination and application of this extension ensure continuous improvement of TCM trial quality throughout the world. 展开更多
关键词 SPIRIT traditional Chinese medicine clinical trial EXTENSION recommendation
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部